Homocysteine Levels in Type 2 Diabetic Patients with Nephropathy and Coronary Artery Disease
Main Article Content
Abstract
ABSTRACT
The aim of the study was to investigate the relationship between plasma homocysteine (Hcy) levels and diabetic vascular complications and family history of diabetes mellitus (DM) and coronary artery disease (CAD) in patients with type 2 diabetes. Fasting plasma total Hcy concentrations and uncomplicated[metabolic parameters were investigated in 116 diabetic patients patients (n = 35), patients with nephropathy (n = 41), patients with CAD (n = and 31 healthy control subjects. Family histories of DM and CAD of the]40) patients were also studied. The plasma Hcy levels were significantly higher in 2.9± 6.5 vs. 9.6 ±the diabetic patients than in the control subjects (12.9 mol/l, Pμ<0.001). There were no differences between uncomplicated diabetic ± 3.5 vs. 9.6 ± patients and control subjects with respect to Hcy levels (9.60.05). The nephropathy group had higher Hcy levels than the>mol/l, Pμ2.9 mol/l, Pμ 3.5 ± 8.8 vs. 9.6 ±uncomplicated group (14.6 <0.05). Similarly, CAD ± 5.5 vs. 9.6±group had higher Hcy levels than the uncomplicated group (13.3 0.05). Hcy did not correlate with lipid parameters and metabolic<mol/l, Pμ3.5 control of diabetes. There was a significant relationship between hyperhomocysteinemia and family history of CAD of patients (38% vs. 12%, P=0.01). The findings suggest that elevated plasma Hcy levels are strongly associated with nephropathy and coronary artery disease in patients with type 2 diabetes. Also the relationship between hyperhomocysteinemia and a positive family history of CAD found in this study suggests that genetic predisposition may be more responsible for the unfavourable effects of hyperhomocysteinemia in macrovascular complications.
The aim of the study was to investigate the relationship between plasma homocysteine (Hcy) levels and diabetic vascular complications and family history of diabetes mellitus (DM) and coronary artery disease (CAD) in patients with type 2 diabetes. Fasting plasma total Hcy concentrations and uncomplicated[metabolic parameters were investigated in 116 diabetic patients patients (n = 35), patients with nephropathy (n = 41), patients with CAD (n = and 31 healthy control subjects. Family histories of DM and CAD of the]40) patients were also studied. The plasma Hcy levels were significantly higher in 2.9± 6.5 vs. 9.6 ±the diabetic patients than in the control subjects (12.9 mol/l, Pμ<0.001). There were no differences between uncomplicated diabetic ± 3.5 vs. 9.6 ± patients and control subjects with respect to Hcy levels (9.60.05). The nephropathy group had higher Hcy levels than the>mol/l, Pμ2.9 mol/l, Pμ 3.5 ± 8.8 vs. 9.6 ±uncomplicated group (14.6 <0.05). Similarly, CAD ± 5.5 vs. 9.6±group had higher Hcy levels than the uncomplicated group (13.3 0.05). Hcy did not correlate with lipid parameters and metabolic<mol/l, Pμ3.5 control of diabetes. There was a significant relationship between hyperhomocysteinemia and family history of CAD of patients (38% vs. 12%, P=0.01). The findings suggest that elevated plasma Hcy levels are strongly associated with nephropathy and coronary artery disease in patients with type 2 diabetes. Also the relationship between hyperhomocysteinemia and a positive family history of CAD found in this study suggests that genetic predisposition may be more responsible for the unfavourable effects of hyperhomocysteinemia in macrovascular complications.